Summary & Overview
CPT 81186: Targeted Androgen Receptor Family-Specific Genetic Test
CPT code 81186 covers a targeted molecular laboratory test that detects specific, family-known variants in the androgen receptor gene linked to Kennedy disease and patterns of X chromosome inactivation. This technical laboratory procedure is clinically important for confirming inherited, familial mutations and for clarifying genetic risk in affected families. Nationally, such targeted tests support precision diagnosis, cascade testing in relatives, and can affect downstream clinical management and genetic counseling demand.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The analysis addresses coverage and payment benchmarks, coding and billing considerations for laboratory technical services, and the clinical context for ordering targeted hereditary testing for androgen receptor–related conditions.
Readers will find a concise explanation of what CPT code 81186 represents, typical service settings, expected documentation elements, comparisons of payer coverage approaches, and relevant policy trends that affect laboratory billing and authorization. Data not available in the input is noted where applicable; the summary focuses on the code’s clinical purpose, common billing usage, and the payer landscape relevant to targeted molecular diagnostic testing.
Billing Code Overview
CPT code 81186 describes a targeted genetic test performed by a laboratory analyst to detect specific changes in the androgen receptor gene (also referred to as CACNA1A in this description) associated with Kennedy disease or X chromosome inactivation. The test is designed to identify family-specific genetic variants known to occur in the patient’s relatives.
Service Type: Targeted molecular genetic testing (technical component)
Typical Site of Service: Clinical or commercial molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged male with progressive neuromuscular symptoms and a family history suggestive of X-linked spinobulbar muscular atrophy (Kennedy disease). The clinician orders targeted genetic testing to detect a specific pathogenic variant in the androgen receptor gene (also referenced as CACNA1A in the provided description) that is known to segregate in the patient’s family. The workflow: the ordering neurologist or geneticist collects a blood or saliva specimen at an outpatient clinic or specialty genetics laboratory. The specimen is shipped to a molecular diagnostics laboratory where a laboratory analyst performs targeted mutation analysis using methods such as PCR sizing, repeat-primed PCR, or targeted sequencing focused on the known familial variant. Results are reported back to the ordering provider; a genetic counselor or neurologist reviews implications for diagnosis, family testing, and reproductive counseling. Typical site of service is an outpatient clinic, specialty genetics clinic, or independent molecular diagnostic laboratory performing technical testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier. | Use when no special circumstances apply. |
| 11 | Professional component. | Use when billing only the physician or professional interpretation component if applicable to a split technical/professional billing arrangement.